Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.
| Revenue (Most Recent Fiscal Year) | $47.07M |
| Net Income (Most Recent Fiscal Year) | $-223.86M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 33.45 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.51 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -409.07% |
| Net Margin (Trailing 12 Months) | -409.07% |
| Return on Equity (Trailing 12 Months) | -30.11% |
| Return on Assets (Trailing 12 Months) | -25.65% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.49 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.49 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $12.07 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.82 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.98 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.10 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 65.12M |
| Free Float | 54.69M |
| Market Capitalization | $1.97B |
| Average Volume (Last 20 Days) | 0.62M |
| Beta (Past 60 Months) | 2.18 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.01% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |